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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of antimicrobial-resistant hospital-acquired infections worldwide
and remains a public health priority in Europe. Nosocomial pneumonia (NP) involving MRSA often affects patients in intensive care units
with substantial morbidity, mortality and associated costs. A guideline-based approach to empirical treatment with an antibacterial agent
active against MRSA can improve the outcome of patients with MRSA NP, including those with ventilator-associated pneumonia. New
methods may allow more rapid or sensitive diagnosis of NP or microbiological conﬁrmation in patients with MRSA NP, allowing early
de-escalation of treatment once the pathogen is known. In Europe, available antibacterial agents for the treatment of MRSA NP include the
glycopeptides (vancomycin and teicoplanin) and linezolid (available as an intravenous or oral treatment). Vancomycin has remained a
standard of care in many European hospitals; however, there is evidence that it may be a suboptimal therapeutic option in critically ill
patients with NP because of concerns about its limited intrapulmonary penetration, increased nephrotoxicity with higher doses, as well as
the emergence of resistant strains that may result in increased clinical failure. Linezolid has demonstrated high penetration into the epithelial
lining ﬂuid of patients with ventilator-associated pneumonia and shown statistically superior clinical efﬁcacy versus vancomycin in the
treatment of MRSA NP in a phase IV, randomized, controlled study. This review focuses on the disease burden and clinical management of
MRSA NP, and the use of linezolid after more than 10 years of clinical experience.
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Introduction
Nosocomial pneumonia (NP) is a hospital-acquired infection
often affecting patients in intensive care units (ICUs) with
substantial morbidity, mortality and costs [1,2]. Methicillin-
resistant Staphylococcus aureus (MRSA) now accounts for a large
proportion of all cases of NP, including ventilator-associated
pneumonia (VAP), in hospital patients worldwide [2–4].
International guidelines recommend that empirical therapy
for NP should include antibiotics targeting MRSA in patients
with late-onset infection and/or when some risk factors are
present to provide adequate coverage [5]. The selection of the
individual antibiotic agent should be based on local patterns of
infection and adjusted according to the microbiology results in
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accordance with good antimicrobial stewardship [5]. For NP,
the recommended anti-MRSA agents are glycopeptides and
linezolid. None of the other new MRSA-effective antibiotics
(e.g. daptomycin, tigecycline, telavancin or ceftaroline) are
recommended for the treatment of MRSA NP, because they
either do not work in the lungs [6,7] or they have restrictions
or have not been approved for treatment of NP. This paper
gives an update on the management of MRSA NP, with a focus
on the use of linezolid after more than 10 years of clinical
experience. In particular, we explore current knowledge
regarding the epidemiology of MRSA in Europe, the burden
of illness, pathogenesis and diagnosis of NP, and new updates
on antibacterial management.
Epidemiology of MRSA in Europe
MRSA is the most important cause of antibiotic-resistant
healthcare-associated infections worldwide and remains a
major health issue in European hospitals [8,9]. Data reported
to the European Antimicrobial Resistance Surveillance Net-
work (EARS-Net) indicated that in 2011, 16.7% of S. aureus
isolates collected from hospital laboratories in 28 countries
were found to be MRSA [9]. In ten of the 28 countries (36%),
the proportion of MRSA was 10–25% (Fig. 1). Six countries
further reported an MRSA proportion of 25–50% and two
countries (Portugal and Romania) had rates above 50%. In
general, the lowest rates of invasive MRSA isolates were found
in the north of Europe (Norway, Sweden, Denmark, Finland,
Estonia), whereas the UK and Ireland, and southern and
eastern European countries, generally had higher rates [9].
Although there has been a general decline in the rate of MRSA
bacteraemia in the UK since 2006 [10] and a sustained
decrease in MRSA in Belgium, France, Germany, Ireland, Spain
and the UK, the rate of MRSA is still more than 25% in eight of
the 28 European countries studied [9]. In 40 Spanish hospitals
participating in a nosocomial infection surveillance programme
in Catalonia (The VINCat Programme) between 2008 and
2010, the yearly mean rate of resistance to methicillin
remained stable for the study period (24–25%), whereas the
mean incidence of new cases of MRSA decreased from 0.65 to
0.54 cases per 1000 patient-days (p was not signiﬁcant) [11].
The recently decreasing or maintained low-level incidence
of healthcare-associated MRSA in many European countries is
encouraging. In a majority of countries, these successes can be
linked to the implementation of multi-faceted preventive
interventions (including measures focusing on screening,
contact precautions, decolonization, antibiotic stewardship,
the update and strengthening of national MRSA guidelines, or
bundles of preventive measures and care) [12]. In the UK, a
bundle of high impact measures, including the mandatory
reporting of all MRSA bacteraemia by the hospital and public
benchmarking of MRSA incidence rates, led to an 18-fold
reduction in the incidence of MRSA healthcare-associated
infections over a 5-year period from 2006 to 2011 [13].
In European countries, MRSA is associated with three main
reservoirs: healthcare institutions, the community and live-
stock [12]. The main burden of MRSA in Europe is within the
healthcare system, but community-acquired (CA-) MRSA has
been increasingly identiﬁed as a cause of hospital-onset and
healthcare-associated infections [14,15]. On the other hand,
hospital-associated clones have also caused infections in the
community [16], suggesting that certain clones have the ability
to cross barriers between hospitals and the community.
FIG. 1. Staphylococcus aureus: percentage
of invasive isolates resistant to methicillin
(MRSA), by country, European Union/
European Economic Area countries,
2008–2011 [9]. Reproduced with
permission from the European Centre
for Disease Prevention and Control.
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CA-MRSA is much more common in the USA; however, in
Europe, this trend may now be shifting [12,14]. Recent data
from Portugal and Spain show that the population structure of
MRSA in the community might mirror that found in the
hospital setting [16,17].
MRSA in ICUs is a global problem. In the Extended
Prevalence of Infection in Intensive Care (EPIC) II study, a
large international study conducted in 75 countries on 1 day in
May 2007, MRSA was isolated in 8.7% of ICU infections in
Western Europe and 10.4% of ICU infections in Eastern
Europe [18]; overall, 63.5% of ICU infections were situated in
the respiratory tract, with a signiﬁcantly higher proportion of
respiratory infections observed in Eastern Europe than
Western Europe (71.6 versus 63.3, p 0.05) [18].
Although the distribution of pathogens causing NP can vary
within units in the same hospital as well as from centre to
centre, both within countries and between countries, MRSA is
commonly isolated in patients with NP in European ICUs.
Koulenti et al. [2] reported that MRSA was isolated in 16% of
patients with NP (21.4% in hospital-acquired pneumonia (HAP)
and 14.6% in VAP). A different study of 315 patients with
ICU-acquired pneumonia in Spain found that the types of
pathogens were similar regardless of whether pneumonia was
acquired during ventilation (VAP) or not (HAP) [19]. The
majority of VAP episodes are the result of the so-called
ESKAPE pathogens, a group of antimicrobial-resistant patho-
gens, which includes Staphylococcus aureus (MRSA), Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa
and Enterobacter species [20]. In the survey of European ICUs,
the most common cause of VAP was Enterobacteriaceae
(43.0%), followed by S. aureus (32.6%), of which 18.0% of
episodes were due to methicillin-susceptible S. aureus (MSSA)
and 14.6% to MRSA [2]. Approximately 20% of VAP episodes
are due to P. aeruginosa [2,21]. However, signiﬁcant variability
has been shown in the distribution of pathogens causing VAP
across Europe. In a classic study of VAP patients enrolled from
four sites (Paris, Barcelona, Montevideo and Seville), the
prevalence of MRSA was shown to be signiﬁcantly lower in
patients from Spain than Paris [22].
Burden of Illness
Nosocomial pneumonia is the second most common hospi-
tal-acquired infection and the leading infection in critical care
[2,3,23]. In a large survey of 27 ICUs in nine European
countries (Belgium, France, Germany, Greece, Italy, Ireland,
Portugal, Spain and Turkey), the overall prevalence of NP was
8.1% (ranging from 0% to 24.5% among participating ICUs), and
the overall incidence of VAP was 18.3 episodes per 1000
ventilator-days [2]. A recent report noted a rise in the
incidence of all-cause NP, all-cause VAP and VAP caused by
MRSA over a 10-year period (1999–2009) in 12 French ICUs.
In this study NP accounted for 9.7% (2330/24 089) of all
infections in the ICU over the study period. Of these, 156/
2330 (6.7%) NP and 144/2153 (6.7%) VAP episodes were
caused by MRSA [24]. A signiﬁcant increase in incidence was
found for NP (annual change +4%; 95% CI 1.03–1.05,
p <0.001); VAP (annual change +5%, 95% CI 1.04–1.06,
p <0.001); and MRSA-VAP (annual change +6%; 95% CI
1.00–1.11, p 0.044) [24]. These trends suggest that antibiotic
stewardship and infection control measures may have led to a
diminished or stabilized incidence of non-VAP MRSA infection
in some countries; however, MRSA is still an important cause
of infection associated with mechanical ventilation.
Nosocomial pneumonia can increase ICU length of stay by
approximately 12 days [2]. In addition, MRSA infection has
been shown to lead to increased morbidity in patients with
NP. In a study of VAP patients in France, MRSA infection was
associated with longer periods of hospitalization, mechanical
ventilation and ICU stay than MSSA infection [25]. Indepen-
dently of other variables analysed, the presence of MRSA
versus MSSA doubled the need for continued ICU stay (hazard
ratio 2.08; p 0.025) [25].
Mortality
Measuring the mortality attributable to VAP is challenging and
prone to different forms of bias. Studies addressing this issue
have produced variable and controversial results. Important
sources of variation include the deﬁnition of VAP, differences in
patient populations (e.g. underlying disease severity), small
sample sizes and the use of inappropriate statistical models
(estimates biased by lead-time bias and competing events) [26].
In an effort to overcome some of these methodology issues, the
mortality attributable to VAP was estimated in a large
multicentre cohort in French ICUs using statistical methods to
account for the time of acquiring VAP, loss to follow up after ICU
discharge and disease severity [27]. It was estimated that only
about 1.0–1.5% of the ICU mortality rate was directly attribut-
able to VAP [27]. A recent meta-analysis estimated the
attributable mortality of VAP using individual patient data for
6284 patients from 24 randomized trials of VAP prevention [28].
The overall attributable mortality of VAP was estimated to be
13%. Higher rates were observed in surgical patients and
patients with mid-range severity scores at admission (Acute
Physiology and Chronic Health Evaluation II (APACHE) score of
20–29). However, attributable mortality was close to 0% in
trauma patients, medical patients and patients with low or high
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severity of illness scores. The overall daily hazard for ICU
mortality after VAP was estimated to be 1.13 (95% CI 0.98–
1.31). The authors concluded that the attributable mortality of
VAP is mainly caused by the risk of dying due to increased length
of ICU stay [28]. These ﬁndings are consistent with those from a
cohort of European ICU patients where, after adjustment for
potential confounders, VAP episodes in trauma patients were
associated with signiﬁcantly lower mortality when compared
with non-trauma patients [29]. Mortality attributable to VAP has
also been shown to increasewith time onmechanical ventilation,
indicating that it is a time-dependent event [30].
A number of factors have been studied in relation to
mortality outcomes in patients with NP, including methicillin
resistance in S. aureus [31–35]. Results from the EPIC II point
prevalence study showed that in ICU patients, MRSA infection
was independently associated with a 50% higher likelihood of
hospital mortality compared with MSSA infection [34]. The ICU
mortality rates among patients with MRSA and MSSA infections
were 29.1% and 20.5%, respectively (p <0.01) and correspond-
ing hospital mortality rates were 36.4% and 27.0% (p <0.01)
[34]. Similar data were reported in the EU/VAP cohort, in which
NP patients with MRSA infection had poorer outcomes
compared with those who had infection due to MSSA (ICU
mortality rates were 33.3% and 10.0%, respectively) [35]. In
contrast, other studies that adjusted for potential confounding
factors, including adequacy of empirical treatment and severity
of illness, demonstrated no difference in hospital mortality
between patients with MRSA and MSSA VAP [31]. A large,
prospective study reporting 474 patients with VAP in a
single-centre in Spain found that patients with MRSA VAP had
signiﬁcantly higher in-hospital mortality (59.5% versus 46.8%;
p 0.02) than patients with VAP caused by other microorgan-
isms; however, MRSA was not found to be an independent risk
factor for in-hospital mortality [33]. Mortality attributable to
VAP was 10.8% in patients with MRSA and 13.2% in patients
with non-MRSA VAP (p was not signiﬁcant) [33]. A multivariate
analysis revealed that independent risk factors for mortality in
VAP patients were advanced age, Charlson co-morbidity index
(an index that predicts the 10-year mortality for patients with a
range of co-morbid conditions), another episode of VAP at
admission and total days on mechanical ventilation. The authors
concluded that poor outcome was not due to the micro-
organism itself, but rather to the underlying condition of the
patient [33]. Bacteraemia is also a complication of NP that is
associated with an almost doubled mortality when compared
with non-bacteraemic NP [33]. Most recently, an analysis of
outcomes in patients with MRSA NP (n = 251) from the
Improving Medicine through Pathway Assessment of Critical
Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP)
database suggested that both pathogen and host factors
inﬂuence the risk of mortality [32]. In this study, all-cause
28-day mortality occurred in 37.1% of MRSA NP patients, and
signiﬁcant risk factors for mortality in the univariate analysis
were age, APACHE II score, AIDS, cardiac disease, vascular
disease, diabetes, SCCmec type II, Panton–Valentine leucocidin
(PVL) negativity and higher vancomycin MIC (all p values were
<0.05). In the multivariate analysis, independent predictors
were APACHE II score (OR 1.09; p <0.001) and age (OR 1.02;
p 0.02) [32].
Pathogenesis
Nosocomial pneumonia is an inﬂammatory process that is
infectious in origin and occurs more than 48 h after hospital
admission [5]. The pathogenesis of NP is multi-factorial,
although the most common mechanism is the aspiration of
microorganisms that colonize the oropharynx or the upper
gastrointestinal tract [5,36]. The causal microorganisms can
come from the hospital environment or from the normal ﬂora
of the patient. Staphylococcus aureus commonly colonizes the
nasal passages but colonization of the lower respiratory tract
can also occur in chronic obstructive pulmonary disease or
when the natural defences are breached (as in the case of
endotracheal intubation), leading to pneumonia [37]. In
patients with endobronchial tubes, a bacterial bioﬁlm, made
of bacterial aggregates, can develop and lead to tracheal
colonization or NP [38]. MRSA can be persistent in bioﬁlm and
this is a potential source for recurrent MRSA pneumonia [39].
Ventilator-associated pneumonia represents a typeofNP that
develops in hospitalized patients aftermechanical ventilation and
is caused by pathogens thatwere incubating or not present at the
time that mechanical ventilation was started [1]. Early-onset
VAP, deﬁned as that which begins within the ﬁrst 96 h of
hospitalization, is typically due to community pathogens includ-
ing antibiotic-susceptible strains of S. aureus, whereas late-onset
infection (that which occurs after 96 h of hospitalization) is
usually due to antibiotic-resistant strains, such as MRSA,
P. aeruginosa, Acinetobacter species and enteric Gram-negative
bacilli [37,40]. In a study of European ICUs, the most common
pathogens isolated in NP patients (n = 827) were Enterobacte-
riaceae (43.8%), S. aureus (32.3%) (MSSA 16.0%; MRSA 16.2%),
P. aeruginosa (23.1%) and A. baumannii (19.1%). Polymicrobial
infection was documented in 32.2% of patients with NP [2].
Risk Factors
Clinical situations that facilitate the aspiration of secretions,
predispose patients to respiratory infection, and reduce local
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defence systems in the respiratory tract are risk factors for NP
[36]. This wide range of risk factors for NP includes old age
and several underlying chronic diseases (e.g. chronic obstruc-
tive pulmonary disease, congestive heart failure, diabetes,
cerebrovascular disease, dementia, cancer, renal failure, liver
failure, autoimmune disease and human immunodeﬁciency
virus infection) [36,41]. Some factors, including co-morbidities,
have also been identiﬁed as more likely in HAP than in
community-acquired pneumonia. These include congestive
heart failure (36.5% versus 21.3, p <0.01); cancer (26.0%
versus 13.0, p <0.01) and risk factors for aspiration pneumonia
(33.7% versus 18.3, p <0.01) [41].
Underlying diseases and speciﬁc risk factors may also
predispose patients to infection with MRSA, as may some
intrinsic factors linked to each hospital or ICU [42]. Rello et al.
[43] examined risk factors and outcomes for patients who
developed VAP due to MRSA versus MSSA. The MRSA-in-
fected patients were more likely to have received steroids
before developing infection, to have been ventilated for
>6 days, to be older than 25 years, and to have chronic
obstructive pulmonary disease than MSSA-infected patients.
Furthermore, mortality related to VAP was signiﬁcantly higher
among patients with MRSA (RR = 20.72, 95% CI 2.78–154.35)
[43]. Trauma patients developing VAP may have different
demographic characteristics and risk factors than non-trauma
patients. In the EU/VAP cohort, trauma patients with VAP
were younger, had lower simpliﬁed acute physiology II scores
(SAPS II) and higher rates of MSSA (30.6% versus 13%, p 0.03)
compared with non-trauma patients) [29].
Factors identiﬁed as independently associated with higher
risk of MRSA infection are shown in Table 1 [33,42,44–46].
These risk factors for MRSA VAP include higher APACHE II
score on admission to the ICU, treatment with any antibiotic
before VAP, pleural effusion, and previous surgery [33]. A
survey of European clinical practice conducted in 2009 asked
respondents to characterize which patients with a clinical
suspicion of NP they considered to be candidates for empirical
anti-MRSA therapy. The majority of respondents considered
that patients with previous colonization or infection with
MRSA, previous hospitalization in high-risk settings such as
nursing homes, high (>20%) local MRSA prevalence, late-onset
infection, previous antimicrobial treatment and MRSA present
in the nasopharynx should be considered at high risk of MRSA
infection and treated empirically with an antimicrobial agent
active against MRSA [42].
Diagnosis
Nosocomial pneumonia is difﬁcult to diagnose. The goals of
diagnosis are to identify which patients have pulmonary
infection; to ensure the collection of appropriate cultures; to
promote the use of early, effective antibiotic therapy (while
allowing for streamlining or de-escalation when possible); and,
to identify patients who have extrapulmonary infection [5].
Current approaches include both clinical and bacteriological
strategies, and the advantages and disadvantages of each are
shown in Table 2 [5,36,47,48].
Clinical Diagnosis
The presence of pneumonia is deﬁned as a new or progressive
radiographic inﬁltrate plus clinical evidence that the inﬁltrate is
TABLE 1. Risk factors for methicillin-resistant Staphylo-
coccus aureus nosocomial pneumonia infection [33,42–44,46]
Previous surgery
Previous hospitalization in the past 12 months
Long length of hospital stay before culture
Levoﬂoxacin use
Macrolide use
Enteral feeding
Duration of mechanical ventilation before the VAP episode
Prior use of antibiotics
High APACHE II score on admission to intensive care unit
Pleural effusion
Prior history of methicillin-resistant S. aureus
Transfer from a nursing home
Late-onset infection
Methicillin-resistant S. aureus presence in the nasopharynx
History of chronic obstructive pulmonary disease
APACHE, acute physiology and chronic health evaluation; VAP, ventilator-
associated pneumonia.
TABLE 2. Advantages and disadvantages of clinical and
microbiological nosocomial pneumonia (NP) diagnosis
[5,36,47,48]
Advantages Disadvantages
Clinical diagnosis All patients suspected of
having NP are treated
Relatively quick diagnosis
Requires no specialized
microbiological methods
Consistently leads to more
antibiotic therapy than when
therapy decisions are based on
the ﬁndings of invasive lower
respiratory tract samples
Clinical pulmonary infection
score has a low speciﬁcity and
sensitivity for diagnosis of NP
Microbiological
diagnosis
Identiﬁes colonizing from
infecting pathogens
Only patients that require
antibiotic therapy
are treated
Contributes to appropriate
antibiotic use
Invasive (if bronchoscopy is
performed)
False-negative cultures can lead
to failure to treat patient or
pathogen
Results are not always
instantaneous
Results are not always
consistent and reproducible
No gold standard for the
diagnosis of NP
Specialized laboratory and
clinical skills required
Choice of method depends on
local expertise, experience,
availability and cost
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of an infectious origin (at least two to three clinical features),
e.g. fever of higher than 38°C, hypoxaemia, leucocytosis or
leucopenia, or purulent secretions [5,36,47,48]. This diagnostic
deﬁnition does not rely on microbiological data, so all patients
with pneumonia are treated, but it can lead to the indiscrim-
inate use of antibiotics [5]. To improve the sensitivity and
speciﬁcity of the diagnosis of pneumonia, a predictor scale was
developed [49], the Clinical Pulmonary Infection Score (CPIS),
which evaluates a series of parameters (including chest
radiography, respiratory secretions, temperature, leucocyte
count, Gram stain and tracheal aspiration culture). Unfortu-
nately, some studies have found the CPIS to have a low
speciﬁcity and sensitivity for diagnosis of NP [50].
Microbiological Diagnosis
Quantitative cultures of lower respiratory secretions (endo-
tracheal aspirates, bronchoalveolar lavage, or protected spec-
imen brush sampling with or without a bronchoscope) can
deﬁne the presence of pneumonia and the aetiological
pathogen [5,51]. This approach contributes to treatment with
appropriate antibiotic therapy, but growth above a threshold
concentration is required to diagnose NP or VAP and to
determine the responsible pathogens; therefore the results are
not instantaneous.
Furthermore, the results of quantitative cultures are not
always consistent or reproducible, endotracheal aspirates are
often contaminated, and speciﬁcity is reduced in patients who
receive antibiotics for suspected NP before sampling [52].
False-negative cultures may lead to failure to treat a patient or
a speciﬁc pathogen. No reference standard currently exists for
the diagnosis of NP by culture of secretions. Specialized
laboratory and clinical skills are required and the choice of
method depends on expertise, availability and cost. Another
disadvantage to this type of diagnosis is the invasive nature of a
bronchoscopy. A detailed review concluded that the sensitivity
and speciﬁcity of non-bronchoscopic techniques versus bron-
choscopic techniques are similar [53]. Although in certain
settings routine microbiological cultures of specimens
obtained before the onset of VAP may be of some value, e.g.
in ICUs facing a very high rate of multidrug-resistant patho-
gens, and/or when the rate of initially inappropriate treatment
is above 10%, overall, there is generally limited value of
surveillance cultures for predicting pathogens in VAP [54]. A
recent diagnostic test accuracy meta-analysis was performed
to analyse whether lower respiratory tract surveillance
cultures accurately predict the causative pathogens of
subsequent VAP in adult patients [55]. Fourteen studies
conducted in various countries including Belgium, France,
Greece, Italy, Spain and the UK were eligible for inclusion and
accounted for 791 VAP episodes. Despite the relatively low
numbers of patients in some subgroups, the meta-analysis
showed a high accuracy of surveillance cultures, with pooled
sensitivities up to 0.75 and speciﬁcities up to 0.92 in
culture-positive VAP. Pooled sensitivity for MRSA was 0.72
(0.55–0.85) and speciﬁcity was 0.98 (0.77–1.00), although this
was based on only four data sets [55]. This analysis provides
evidence of the beneﬁt of surveillance cultures of the lower
respiratory tract in predicting bacterial pathogens in VAP ICU
patients, particularly the absence of MDR pathogens.
The combination of Gram stain examination of both plugged
telescoping catheter and endotracheal aspirate may contribute
to the early diagnosis of NP in about two-thirds of mechan-
ically ventilated patients, and guide the empirical therapy when
needed. In the remaining one-third of patients, the Gram stain
examination is not helpful in predicting NP [56].
New Diagnostic Approaches
New methods may allow more rapid or sensitive diagnosis of
NP or microbiological conﬁrmation in patients with NP. PCR
of 16S rRNA improves the detection of bacteria in pleural
effusion samples versus conventional culture [57]. An over-
view of the commercially available PCR techniques suggested
that currently PCR can supplement but not replace specimen
culture, as the complete determination of antibiotic resistance
can currently only be performed on isolated strains [58].
Other promising novel diagnostic techniques include a
real-time array, which can detect MRSA in VAP in 1 day
(Bogaerts P et al. 51st Interscience Conference on Antimi-
crobial Agents and Chemotherapy (ICAAC); 17–20 September
2011, abstract D-1287), and a new test which allows
identiﬁcation of MRSA and MSSA in clinical isolates in 1 h
but that has not been tested in direct clinical samples from the
lower respiratory tract [59], and quantitative PCR of
mini-bronchoalveolar lavage samples which can rapidly detect
the mecA gene [60]. Recent data also show that direct
examination of bronchoalveolar lavage ﬂuid enables rapid
diagnosis of VAP caused by Gram-positive cocci (Chastre,
personal communication).
New assays are also being developed that allow rapid and
economical detection of PVL, a cytotoxin and key virulence
determinant in CA-MRSA necrotizing pneumonia. Diagnostic
tests include an ELISA and immunochromatographic test
targeting PVL [61] and a lateral ﬂow assay based on
monoclonal antibodies [62]. Due to the continued migration
of CA-MRSA into the healthcare setting, the detection of
PVL-producing strains in patients with NP may help to guide
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antimicrobial treatment regimens based on the presence or
absence of PVL.
Biomarkers
Although procalcitonin detection has minimal utility for the
diagnosis of NP [63,64], it has shown value as a prognostic
indicator and may be useful as a guide to antimicrobial therapy,
particularly when to consider antibiotic discontinuation, in
patients with VAP [65]. Some studies have suggested that
procalcitonin guidance might also be helpful in immunocom-
promised ICU patients with suspected pulmonary infection
[66,67]. However, bacterial infections are not the only factors
that can lead to procalcitonin elevation in this setting.
Therefore, pending additional results obtained in larger
interventional trials, clinical decision-making cannot for the
moment be justiﬁed based on procalcitonin alone in immuno-
suppressed patients. Detection of the triggering receptor
expressed on myeloid cells (sTREM-1) in bronchoalveolar
lavage ﬂuid has also been shown to be useful for diagnosing
bacterial infection in VAP patients [68], however, not all
studies have conﬁrmed the clinical utility of this marker
[69,70].
Principles of Antibacterial Treatment
There are two principles guiding the strategy of antibacterial
therapy for NP. The ﬁrst is the initial administration of
adequate treatment with an antibacterial agent(s) active against
the causative pathogen(s). The second is the shortening or
narrowing down of treatment (de-escalation) once the caus-
ative pathogen is known and risk factors have been taken into
consideration [40,71]. When NP is suspected, the initial
treatment regimen is often chosen without the identiﬁcation of
the causative pathogen. Knowledge of the local epidemiology
and pathogens associated with NP can help in the selection of
the correct empirical treatment [40,72]. In Europe, available
antibacterial agents for the treatment of MRSA NP include the
glycopeptides (vancomycin and teicoplanin) and linezolid [73–
75]. Of these, only linezolid is available as an oral treatment
[76].
Adequate versus Inadequate Treatment
A guideline-based approach based on local antibiotic suscep-
tibility patterns can improve the outcome of patients with NP
[77]. Several studies have reported that inadequate treatment
of nosocomial infection, including those due to MRSA,
increases all-cause and infection-related mortality [78,79].
Furthermore, a delay in appropriate antibiotic treatment can
lead to increased mortality for patients with MRSA infections
[79] and increased ICU length of stay in patients with NP [80].
Appropriate antibiotic therapy is commonly deﬁned as the use
of an antimicrobial agent that is correct on the basis of all
available clinical, pharmacological and microbiological evidence.
It includes narrowing the spectrum when culture and pheno-
typic results are available, using appropriate dosages and
dosing intervals, and respecting additional principles of the
judicious prescription of antibiotics [81]. Although deﬁnitions
may vary in the literature, inadequate antimicrobial therapy is
commonly deﬁned as the microbiological documentation of an
infection with a causative pathogen that is not being effectively
treated [81].
When is MRSA Coverage Required?
Although predisposing factors to MRSA NP have been studied
extensively [41,43–46], this infection is commonly associated
with inadequate initial treatment [82–85]. Even at the current
time, the assessment of patients at risk of MRSA infection is
not always performed well. As reported by Bouza et al. [33],
70% of patients with MRSA VAP in a large hospital in Spain
were treated empirically with ineffective antibiotics.
A large number of studies evaluating MRSA risk factors have
been published [86–89]. These demonstrate that the utility of
trying to identify patients from such approaches to target
MRSA treatment is highly variable and does not achieve
dependable positive levels of accuracy although negative
prediction tends to be very good. The factors identiﬁed as
being associated with MRSA infection vary depending upon the
clinical setting of the patient e.g. ICU versus community, the
clinical condition in question e.g. pneumonia versus orthopae-
dic trauma, and the background rate of MRSA in terms of high
and low prevalence areas [86–89]. The presence of multiple
risk factors improves the likelihood of the presence of MRSA
sepsis [88]. Hence, to assure adequate therapy, empirical
MRSA coverage is required in patients previously identiﬁed as
colonized or infected by this strain [42], when local prevalence
is high, in patients with previous hospitalization in high-risk
settings such as nursing homes or chronic haemodialysis
centres, and when Gram staining of respiratory secretions
shows Gram-positive cocci in late-onset infection and/or after
previous antimicrobial treatment [5].
Patterns of empirical antibiotic prescribing for NP were
examined in nine European countries (Belgium, France,
Germany, Greece, Italy, Ireland, Portugal, Spain and Turkey)
[80]. Across Europe, anti-MRSA agents were prescribed in
38.4% of VAP episodes. For NP, vancomycin (20.2%) was the
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most commonly prescribed anti-MRSA agent followed by
linezolid (13.9%) and teicoplanin (11.4%) [80]. Interestingly, the
only variables found to be signiﬁcantly associated with
prescription of an anti-MRSA agent were length of stay
>5 days and Acinetobacter prevalence >10%, showing that
empirical choice was inﬂuenced by factors other than the
known risk factors for MRSA (e.g. previous use of antibacte-
rials, previous hospitalization, or MRSA prevalence >10%).
Duration of Treatment
Few data are available on the optimal duration of antibiotic
therapy for MRSA NP. For VAP patients, an 8-day regimen was
shown to be as effective as a 15-day regimen, without affecting
survival [90]. Similar ﬁndings were reported in a small study of
15 patients with MRSA NP; however, regardless of the
appropriateness of initial antibiotic therapy, MRSA NP was
associated with poor clinical resolution and a longer duration
of mechanical ventilation [91]. A systemic review of eight
studies, concluded that a short course (7–8 days) of therapy
may be appropriate for patients with VAP that is not due to
non-fermenting Gram-negative bacteria [92]. In current clinical
practice, use of an individual-based strategy is recommended,
and the duration of treatment has been generally limited to
7–10 days in early NP and possibly lengthened to 14 days in
late NP due to MRSA [36,42].
De-escalation
Initial empirical therapy for NP is often challenging because
many patients are infected with multidrug-resistant pathogens.
The need for adequate coverage can lead to broad-spectrum
empirical therapy, which can represent antibiotic overuse and
promote resistance. To address this problem, de-escalation
therapy has been proposed, with the goals of reducing the
number of drugs, the spectrum of therapy, and the duration of
therapy [5,71]. Treatment guidelines recommend de-escalation
of empirical antibiotic therapy for NP based on microbiological
cultures and the clinical response of the patient [5]. A strategy
of early de-escalation was supported by a recent study
suggesting that early antibiotic discontinuation (within 1 day
of ﬁnal negative culture) in patients with clinically suspected
VAP and negative quantitative bronchoalveolar lavage cultures
did not affect mortality and was associated with a lower
frequency of multidrug-resistant superinfections than late
antibiotic discontinuation (more than 1 day after ﬁnal negative
culture) [93]. Further evaluation of this strategy in different
hospitals is warranted.
Pharmacokinetic/Pharmacodynamic
Parameters
Optimal dosing and the pharmacokinetic/pharmacodynamic
characteristics of antimicrobial agents are among the many
factors to consider in the treatment of MRSA NP infections
[94,95]. Antibiotic penetration into the site of infection, to
provide pharmacologically active drug concentrations at the
site of action, is important to therapeutic response [95–97]. In
NP, successful treatment may depend on adequate delivery of
free (unbound) concentrations of antibiotic to the infected
area [94–96]. In particular, epithelial lining ﬂuid concentrations
are considered important determinants for successful treat-
ment of NP as pulmonary pathogens are most often located in
epithelial lining ﬂuid [96].
The penetration of linezolid and vancomycin into pulmonary
tissue and respiratory secretions has been studied in healthy
volunteers and patients with NP [95,98–103]. Several studies
have measured antibacterial concentrations in epithelial lining
ﬂuid using bronchoalveolar lavage sampling; however, the
clinical relevance of these pharmacokinetic measurements is
not yet clearly established. Linezolid has demonstrated high
penetration to the epithelial lining ﬂuid in healthy volunteers
(approximately 400%), bronchoscopy patients (206%) and
critically ill patients with VAP (104%) [95,99,102,103].
Although higher vancomycin serum concentrations may be
necessary to achieve adequate lung concentrations in patients
with MRSA NP, linezolid demonstrates good penetration into
the lung with sustained concentrations above the MIC for
MRSA, throughout the dosing interval [95].
Animal Models of Infection
As stated above, few studies have examined the clinical
relevance of pharmacological parameters that may inﬂuence
treatment outcomes in MRSA NP. Experimental animal models
have been developed to further explore this question. Luna
et al. [104] induced experimental MRSA pneumonia that
produced severe derangement in lung pathology and haemo-
dynamic and respiratory physiology in piglets. Using this model,
they explored outcomes following linezolid or vancomycin
administration in both the mechanically ventilated and
non-mechanically ventilated settings. The results showed more
favourable outcomes in the group receiving linezolid than in
the group given vancomycin, including less pathological com-
promise, better clearance of MRSA and a longer survival [104].
Martinez-Olondris et al. [105] also assessed the efﬁcacy of
linezolid compared with vancomycin in an animal model of NP
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induced by MRSA in mechanically ventilated pigs. In this model,
treatment with linezolid led to better microbiological and
histopathological responses than intermittent or continuous
infusion with vancomycin, and showed more favourable
pharmacokinetic/pharmacodynamic characteristics [105]. The
observed median lung tissue/serum ratios were 0.49 for
vancomycin and 0.75 for linezolid—evidence of good pene-
tration of linezolid into the site of infection [105]. In the same
animal model, systemic treatment with linezolid limited
endobronchial tube bioﬁlm development and MRSA burden
[106]. Bioﬁlm linezolid concentration was 19-fold above the
linezolid MIC, whereas vancomycin bioﬁlm concentration was
consistently below or close to the vancomycin MIC [106]. In
an experimental model of MRSA pneumonia in neutropenic
mice, linezolid (30 mg/kg) was shown to be more effective
than a pharmacodynamically optimized dose of vancomycin
(110 mg/kg; attaining an AUC/MIC ratio >400) in reducing
bacterial lung concentrations [107].
Animal models have also been used to explore the effects of
linezolid and vancomycin on in vivo bacterial toxin production
by a PVL-producing MRSA strain (clone USA300) and survival
outcomes in a rabbit model of necrotizing pneumonia [108]. In
this model early treatment with linezolid (1.5 h after infection)
resulted in signiﬁcant suppression of exotoxin synthesis,
including PVL and a-haemolysin, as well as reduced production
of the neutrophil-chemoattractant interleukin-8 in the lungs,
and led to improved survival outcomes compared with
vancomycin [108]. Although the extrapolation of data from
animals to humans is limited, the ﬁndings of all these animal
models are consistent with clinical studies showing better
outcomes associated with the use of linezolid than vancomycin
for the treatment of MRSA NP [109,110].
Limitations of Vancomycin
Vancomycin, a cell wall synthesis inhibitor, is a recommended
parenteral therapy for MRSA infections but there is evidence
that it may be a suboptimal therapeutic option in critically ill
patients with NP [111,112]. The limitations of vancomycin are
listed in Table 3 [113–117]. There are concerns about its slow
bactericidal activity as vancomycin kills staphylococci more
slowly than b-lactams in vitro, particularly at higher inocula
(107–109 CFU) [115], as well as the emergence of strains that
are resistant to vancomycin (VRSA) or have intermediate
susceptibility to vancomycin (VISA) in which MICs of vanco-
mycin are >2 mg/L, as well as strains with vancomycin MICs
≤2 mg/L that exhibit heteroresistance (so-called hVISA strains)
[8]. The frequency of such strains shows considerable
geographical variation, and they are associated with clinical
failure of glycopeptides [122–124]. Additionally, a possible
increase in the vancomycin MIC of MRSA isolates within the
susceptible range (1.0–2.0 mg/L) has also been associated with
a lack of response to treatment [125]. Vancomycin is
considered inferior to b-lactams for MSSA bacteraemia and
infective endocarditis [115]. Other concerns with vancomycin
include its highly variable tissue penetration depending upon
the degree of inﬂammation, limited penetration into lung
epithelial lining ﬂuid [100,126], and difﬁculty in reaching
optimal doses [115]. In a study of 200 patients, Kullar et al.
[119] assessed the effectiveness of a newly constructed
vancomycin dosing nomogram (based on weight and renal
function) in achieving target trough serum concentrations of
15–20 mg/L, suggested by the vancomycin consensus guide-
lines [5,127]. They found that only 58% of patients achieved
the target trough (median 17.5 mg/L), but the performance of
the nomogram improved to 80% when the trough range was
adjusted to 13–22 mg/L [119]. The authors emphasized that
caution should be applied when using this nomogram, and it
should not replace clinical judgement based on pharmaco-
kinetic/pharmacodynamic targets and clinical response [119].
In the ICU setting, patients with sepsis often require higher
than conventionally recommended doses of vancomycin;
however, optimal dosing regimens remain unresolved [128],
and there is an increased risk of nephrotoxicity with higher
doses of vancomycin [121].
Vancomycin displays predominantly time-dependent phar-
macodynamic properties. For both vancomycin and linezolid,
the most important pharmacokinetic/pharmacodynamic
parameter for clinical and microbiological success is the ratio
of the area under the drug concentration–time curve over
24 h to the MIC (24-h AUC/MIC) [98,130]. A limitation of
vancomycin is that standard doses of 1.5 g every 12 h often fail
to reach the target AUC0–24 h/MIC [111,116]. Using a series of
Monte Carlo simulations, Patel et al. [111] assessed the
probability of achieving a target AUC/MIC ratio ≥400 for
TABLE 3. Limitationsofvancomycin[8,100,112,113,115–121]
Slow bactericidal activity
Time-to-MRSA eradication is longer than with other anti-staphylococcal
antibacterials
Emergence of resistant strains (VRSA, VISA and hVISA)
MIC change for S. aureus, MRSA and MSSA has been observed in the clinical
setting
Treatment failures increase with MIC
Tissue penetration is variable and depends on degree of inﬂammation
Limited penetration into lung epithelial lining ﬂuid
Optimizing therapy (achieving area under the inhibitory curve/MIC ≥400) or target
trough serum concentrations (15–20 mg/L) is difﬁcult
Increased risk of nephrotoxicity as a function of trough levels and duration of
therapy
hVISA, Staphylococcus aureus with intermediate heteroresistance to vancomycin;
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; VISA,
S. aureus with intermediate resistance to vancomycin; VRSA, vancomycin-resistant
S. aureus
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vancomycin regimens of varying intensity (0.5 to 2.0 g every
12 h) when trough concentrations were between 15 and
20 mg/L (the level recommended by the ATS/IDSA guidelines)
[5]. Their results showed that at an MIC of 2 mg/L, even the
most intense dosing regimen yielded a low probability of target
attainment (57%), while increasing the probability of nephro-
toxicity by 35% [111]. This is relevant in light of a recent study
showing that nearly half (49%) of patients with MRSA NP had
isolates with high vancomycin MICs (≥1.5 mg/L), and patients
infected with these MRSA strains had lower clinical response
rates than patients with low vancomycin MICs [131]. High
vancomycin MICs have been associated with increased mor-
tality in patients with MRSA NP [32].
Two therapeutic manipulations frequently used in an
attempt to improve outcomes of vancomycin therapy are
either to alter the method of administration or to administer it
in combination with another antibiotic. However, continuous
infusion vancomycin regimens are unlikely to improve patient
outcome compared with intermittent dosing [132,133]. In a
study of ICU patients at Erasme Hospital in Brussels, Belgium,
acute kidney failure occurred in almost 25% of critically ill
patients with sepsis treated with a continuous infusion of
vancomycin [134]. Vancomycin concentrations and duration of
therapy were the strongest variables associated with the
development of early and late kidney failure during therapy,
respectively [134]. However, many European ICUs are using
continuous infusion and a large-scale multicentre study (the
Deﬁning Antibiotic Levels in ICU patients (DALI) Study) is
currently underway in 60 ICUs throughout ten countries in
Europe (including Belgium, France, Greece and Spain) to
describe antibiotic dosage and target levels and the clinical
outcomes of patients administered intermittent dosing versus
extended or continuous infusion [135]. A preliminary publica-
tion from the DALI Study examined the pharmacokinetics of
teicoplanin in critically ill patients from eight European ICUs.
The results showed that teicoplanin-free plasma concentra-
tions were highly variable ranging between 0.3 and 10 mg/L
(mid dose) and 0.1 and 4.5 mg/L (trough), respectively, and
therefore difﬁcult to predict via algorithms [136]. The results
underscore that dosing of teicoplanin is difﬁcult and that
under-dosing can occur commonly with standard infusion.
Aggressive dosing and prolonged administration of vanco-
mycin have also been associated with a greater risk of
nephrotoxicity in patients without sepsis
[114,120,121,137,138]. Vancomycin-induced nephrotoxicity
has been reported in 10–20% and 30–40% of patients following
conventional and high doses of vancomycin therapy [137]. In
the IMPACT-HAP observational study, nephrotoxicity
occurred in 29 of 188 (15.4%) NP patients treated with
vancomycin in the ICU [120]. Most recently a systematic
review and meta-analysis of the available evidence (15 studies)
on vancomycin-induced nephrotoxicity found that higher
trough levels (≥15 mg/L) were associated with an increased
risk of nephrotoxicity (OR 2.67; 95% CI 1.95–3.65) relative to
lower troughs (<15 mg/L) and the risk of nephrotoxicity
increased with duration of therapy [121].
Combination therapy with vancomycin also has little
supportive evidence. The addition of rifampicin to vancomycin
was investigated in a prospective, randomized, open label study
of MRSA pneumonia in Korea [139]. Outcomes were slightly
better in the group that received combination therapy;
however, the group that received rifampicin tended to have
more severe adverse events and the emergence of rifampicin
resistance in a signiﬁcant number of isolates was concerning
[139].
Due to the increasingworldwide prevalence ofMRSA isolates
having vancomycinMICs at or just below a breakpoint of 2 mg/L,
the European Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) has reduced the breakpoint for vancomycin to
2 mg/L [140]. Although themajority of clinicalMRSA isolates are
still classiﬁed as susceptible, the available clinical evidence argues
for a method-dependent breakpoint of 1.0 mg/L (Etest), which
would classify many strains as resistant, or at best intermediate.
Glycopeptide-intermediate S. aureus, particularly heteroge-
neous glycopeptide-intermediate S. aureus, remains difﬁcult to
detect in the routine practice of medical microbiology, even by
the determination of MICs [141]. Alternative therapies should
be considered for NP patients with MRSA infections with a
vancomycin MIC (≥1 mg/L) [98,127,142]. Furthermore, as a
consequence of the increased risk of nephrotoxicity with
vancomycin, US guidelines have recommended that linezolid
may be preferable to vancomycin for the treatment of
patients with renal impairment and patients who are at
increased risk of nephrotoxicity or on concomitant
nephrotoxic drugs [5].
Linezolid: Susceptibility and Resistance
Linezolid, an oxazolidinone and protein translation inhibitor, is
active against multiple Gram-positive pathogens, including
multidrug-resistant strains [143]. Linezolid inhibits protein
synthesis by binding to the domain V region of the 23S rRNA
gene. Linezolid was ﬁrst licensed in the USA and Europe in
2001 and has been available for clinical use for over 10 years.
In Europe, linezolid is indicated to treat NP, when known or
suspected to be caused by susceptible Gram-positive bacteria;
community-acquired pneumonia, when known or suspected to
be caused by susceptible Gram-positive bacteria; and, compli-
cated skin and soft tissue infections, when microbiological
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testing has established that the infection is known to be caused
by susceptible Gram-positive bacteria [75]. The Zyvox
Annual Appraisal of Potency and Spectrum Programme
(ZAAPS) monitors linezolid pathogen susceptibility in Europe.
In a study carried out from 2002 to 2009, no evidence of
resistance to linezolid was found during this 8-year period
[143]. Most recently, in 2011 linezolid was shown to maintain
its potency and spectrum against 8059 Gram-positive isolates
collected from 79 sites in 33 countries [144]. Linezolid MIC90
values were 2 mg/L for both MSSA and MRSA, and 99–100%
susceptibility to linezolid was demonstrated by MSSA, MRSA,
coagulase-negative Staphylococcus, Enterococcus sp., Strepto-
coccus pneumoniae, viridans group streptococci and b-haemolytic
streptococci isolates [144]. In addition, for 2011, 26 European
countries reported susceptibility data for 22 653 S. aureus
isolates, of which only 14 (0.06%) were non-susceptible to
linezolid [9].
Although rare, linezolid resistance is most often due to
target site mutations of the 23S rRNA gene and are associated
with prolonged and/or intermittent use of linezolid [145–147].
Outbreaks of linezolid-resistant MRSA, coagulase-negative
Staphylococcus and enterococci due to dissemination of
resistant clones have been reported [146,148–150]. An
outbreak of linezolid-resistant MRSA due to acquisition of
an RNA methyltransferase resistance gene (cfr) was ﬁrst
reported in 2008 in an ICU in Madrid [146]. The linezolid
MIC50 was 32 mg/L (range, 16–32 mg/L). This outbreak was
associated with nosocomial transmission and extensive usage
of linezolid. Evidence suggests that horizontal and interclonal
transmission of resistance may occur [148,150,151]. Emer-
gence of this new mobile resistance determinant, cfr, requires
close monitoring [152]. Although uncommon, the cfr gene has
been shown to co-occur with other linezolid-resistance
mechanisms, and MICs up to 256 mg/L were recently
reported in clinical isolates of cfr-mediated linezolid-resistant
Staphylococcus epidermidis harbouring a combination of resis-
tance mechanisms [153]. In the 2011 ZAAPS survey, there
were 14 linezolid-resistant strains detected from seven
countries (Brazil [5], France [1], Germany [2], Greece [2],
Italy [2], Ireland [1] and Spain [1], representing ﬁve species
(Enterococcus faecium, Staphylococcus capitis, S. epidermidis,
Staphylococcus hominis and Staphylococcus lugdenensis) [144].
The mobile cfr gene was noted in two species having elevated
linezolid MIC values, one was a Staphylococcus haemolyticus
isolate with an MIC of 4 mg/L [144]. VRSA also remains rare,
with only a few cases conﬁrmed worldwide; however, the ﬁrst
case of VRSA in Europe was recently reported in Portugal
[154]. This worrying ﬁnding reinforces the need for continued
surveillance, infection control and antimicrobial stewardship
initiatives.
Treatment Guidelines
In 2005, the American Thoracic Society (ATS)/Infectious
Diseases Society of America (IDSA) issued guidelines for
initial empirical antibiotic therapy for HAP, healthcare-associ-
ated pneumonia and VAP [5]. In 2011, the IDSA also issued
guidelines for the treatment of MRSA infections, including
MRSA NP [115]. Both guidelines recommend linezolid and
vancomycin for the treatment of NP due to MRSA [5,115]. The
ATS/IDSA guidelines also state that linezolid is a preferred
alternative to vancomycin in the treatment of MRSA NP in
patients with renal impairment, concomitant aminoglycoside
use, and in those who are older than 65 years. If patients are
failing on vancomycin, a switch to linezolid is recommended
[5,155], and linezolid may be preferred in patients at increased
risk of nephrotoxicity or on concomitant nephrotoxic drugs
[5].
There are also a number of European guidelines for the
treatment of NP including those issued by the European HAP
Working Group [47] which included a Task Force from the
European Respiratory Society, the European Society of
Clinical Microbiology and Infectious Diseases and the Euro-
pean Society of Intensive Care Medicine, as well as coun-
try-speciﬁc guidelines from the British Society of
Antimicrobial Chemotherapy [48], the German Sepsis Society
[156] and the Spanish Society of Pneumology and Thoracic
Surgery (SEPAR) [36]. In Germany there is also a joint
published guideline on NP from the German Society for
Anaesthesiology and Intensive Care Medicine, the German
Society for Infectious Diseases, the German Society for
Hygiene and Microbiology, the German Society of Pneumol-
ogy and the Paul-Ehrlich-Society for Chemotherapy [157].
All of these guidelines recommend the use of vancomycin or
linezolid for treatment of MRSA NP.
In 2011, a systematic review and meta-analysis of eight
randomized, controlled trials (1641 patients) of pneumonia
concluded that the evidence does not support the superiority
of linezolid over glycopeptide antibiotics for the treatment of
NP [158], and decisions between linezolid or glycopeptides for
empirical or MRSA-directed therapy of NP should depend on
availability, resistance patterns, routes of delivery and cost,
rather than presumed differences in efﬁcacy [158]. However,
this meta-analysis, as well as most of the current treatment
guidelines, did not include data from the ZEPHyR study, the
most recent randomized clinical trial of linezolid versus
vancomycin for the treatment of patients with culture-proven
MRSA NP [110].
A meta-analysis, published in 2013 compared the efﬁcacy
and safety of linezolid with vancomycin for the treatment of
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MRSA-related infections using data from nine randomized
controlled trials (5249 patients) [159]. In contrast to the
previous meta-analysis, the trials included were heterogeneous
in terms of patient populations and drug administration route
and focused only on vancomycin as a comparator. Two of the
trials (one was the ZEPHyR study) included patients with
pulmonary-related MRSA infection, and four trials included
patients with skin and soft tissue infection-related MRSA
infection. The results indicated that linezolid was associated
with signiﬁcantly higher efﬁcacy compared with vancomycin for
MRSA-related infection in terms of clinical treatment success
(OR 1.77, 95% CI 1.22–2.56) and microbiological treatment
success (OR 1.78, 95% CI 1.22–2.58). In the subgroup of
patients with pulmonary-related MRSA infection, clinical
success was signiﬁcantly greater with linezolid than vancomy-
cin (OR 1.56, 95% CI 1.01–2.39). Although no difference was
found regarding the overall incidence of drug-related adverse
events between treatment groups, linezolid was associated
with signiﬁcantly fewer patients experiencing abnormal renal
function compared with vancomycin (OR 0.39, 95% CI 0.28–
0.55), providing further evidence of the advantages of linezolid
for the treatment of MRSA-related infection [159].
Clinical Management of MRSA NP with
Linezolid
Efﬁcacy
Since its initial approval, much clinical research data has been
published on the pharmacokinetics, efﬁcacy, safety and health
economic outcomes of linezolid. The efﬁcacy of linezolid versus
vancomycin for the treatment of patients with NP due to
S. aureus was ﬁrst demonstrated in two phase III prospective,
randomized, double-blind clinical trials in 2001 and 2003
[160,161]. These data were recently conﬁrmed in the ZEPHyR
study (a phase IV, prospective, randomized, double-blind,
multicentre, non-inferiority trial published in 2012), which
assessed the efﬁcacy, safety and tolerability of linezolid versus
vancomycin in adult patients with culture-conﬁrmed MRSA NP
[110]. The results showed that for the primary endpoint,
linezolid was statistically signiﬁcantly superior to vancomycin,
with a signiﬁcantly higher clinical response at the end of study in
the per-protocol (PP) population (57.6% versus 46.6%; p 0.042)
[110]. Linezolid led to a signiﬁcantly higher microbiological
response than vancomycin at the end of the study (58.1%
versus 47.1%, 95% CI 4–21.5) [110]. Response differences
between linezolid and vancomycin were consistent across most
patient subgroups (e.g. patients with bacteraemia, APACHE II
score ≥20; vancomycin MIC <1 and vancomycin MIC = 1)
[110]. An improved clinical response with linezolid (58%)
versus vancomycin (39%) was also shown in patients with
diabetes (Equils O and Huang DB. 51st Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy (ICAAC);
17–20 September 2011 (abstract A-215)). A post hoc analysis
of the patients treated with vancomycin in the ZEPHyR trial
reported that the median maximum vancomycin trough level
was ≥14.1 lg/mL and the majority of MRSA isolates had a
vancomycin MIC of ≤1.0. No relationship was found between
vancomycin trough levels and outcomes [162]. The average
duration of treatment was 10 days in both arms. No clinical
trial has shown a beneﬁt of longer glycopeptide therapy [90].
Safety
The safety and tolerability proﬁles of linezolid and vancomycin
have been documented in clinical trials and post-marketing
reports. Clinical concerns include an increased risk of myelo-
suppression (including anaemia, leucopenia, pancytopenia and
thrombocytopenia) with prolonged use of linezolid (more than
14 days of therapy) as indicated in the summary of product
characteristics [75], and of nephrotoxicity with use of vanco-
mycin [73]. Patients who receive long-term therapy with
linezolid must be managed by careful monitoring for adverse
events [163]. The safety proﬁles of linezolid and vancomycin
were evaluated in patients with MRSA NP in the ZEPHyR study.
In this clinical trial the incidence of thrombocytopenia was 1.3%
for patients treated with linezolid and 2.2% for patients treated
with vancomycin [110]. Anaemia was reported in 5.2% and 7.2%
of patients, respectively. Hence, frequent haematological abnor-
malities were not observed, possibly because of the short
duration of therapy. Nephrotoxicity occurred nearly twice as
frequently with vancomycin as with linezolid (18.2 versus 8.4%),
and was seen in 16.2% of vancomycin-treated patients with
normal renal function (glomerular ﬁltration rate <50 mL/min)
and 18.8% of patients with impaired renal function (glomerular
ﬁltration rate >50 mL/min) at baseline. Furthermore, the
incidence of renal failure, renal impairment and/or azotaemia
was higher in patients treated with vancomycin (7.3% versus
3.7%). The authors noted that the higher rate of nephrotoxicity
with vancomycin may partially reﬂect the use of adjusted
vancomycin doses in this trial [110], as recommended by current
clinical guidelines [5,115].
Mortality
In the ZEPHyR study, all-cause 60-day mortality rates were
comparable in the linezolid and vancomycin treatment arms
(15.7% and 17.0% (intention-to-treat population), respectively)
[110]. Several authors have commented on the lack of
mortality difference between the treatment groups;
[164,165]; however, the ZEPHyR study was not designed
nor statistically powered to detect a mortality difference [110].
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Health economic outcomes
The economic consequences of hospital-acquired respiratory
tract infections are considered to be high [166]; however, few
studies have examined the medical costs of NP in Europe.
Leistner et al. [167] estimated the attributable hospital cost
per patient for a ventilator-associated lower respiratory tract
infection acquired in an ICU in Germany as €17 015 (signif-
icantly higher than for patients who did not acquire a lower
respiratory tract infection; p <0.001). In Germany, the costs of
MRSA NP were also estimated in a case–control study
(conducted during 2005–2007) [168] in which 41 patients
with MRSA NP and 41 patients with MSSA NP were matched
for age, underlying disease severity and hospital length of stay.
Overall hospital costs per patient were estimated as €60 684
for MRSA NP versus €38 731 for MSSA NP; a signiﬁcant
difference (p 0.01). The attributable costs for MRSA NP per
patient were €17 282 (p <0.001) [168].
Health economic evaluations are now an important com-
ponent of antibiotic assessment in most countries. The cost
effectiveness of linezolid for the treatment of MRSA NP has
been estimated using a decision-model approach in the USA,
Latin America and Europe. Commonly reported outcomes
include length of hospital stay, quality-adjusted life-years, drug
costs, costs per episode of infection, and total hospital costs. In
these studies, the higher acquisition cost of linezolid was found
to be offset by improved survival and, in some cases, a
reduction in total healthcare costs; hence linezolid was found
to be a cost-effective alternative to vancomycin [169–172].
In a post hoc analysis of the global, multicentre ZEPHyR
trial, MRSA NP patients treated with linezolid or vancomycin
had comparable treatment costs and health resource use,
including days on mechanical ventilation and length of hospital
stay (Solem CT et al. 17th International Society for Pharmaco-
economics and Outcomes Research (ISPOR), 2-6 June 2012,
oral presentation IN-4). A similar economic analysis using data
from the ZEPHyR trial was conducted from the Spanish-payer
perspective. In this study, overall healthcare resource use and
costs were similar between linezolid and vancomycin. How-
ever, linezolid was associated with a signiﬁcantly lower
incidence of renal failure than vancomycin, and when renal
failure did occur, linezolid patients tended to have lower
healthcare resource use and total cost than vancomycin
patients [173].
A retrospective, non-interventional study used data from
two US administrative databases to compare re-hospitalization
rates and total direct medical costs of NP patients treated
post-discharge with linezolid or vancomycin in the real-world
setting. In this study, linezolid was associated with a 66% lower
rate of re-hospitalization after 42 days relative to vancomycin
[174].
Conclusions
Nosocomial pneumonia infections are one of the leading
causes of death worldwide and MRSA NP remains an
important healthcare burden in Europe. The economic costs
are considerable. A guideline-based approach to treatment
based on local antibiotic susceptibility patterns can improve
the outcome of patients with MRSA NP, including those with
VAP. Linezolid has demonstrated statistically superior clinical
efﬁcacy versus vancomycin and an acceptable safety and
tolerability proﬁle in the treatment of MRSA NP in a phase
IV clinical trial [110]. Antimicrobial resistance to linezolid is
rare and it is an efﬁcacious and well-tolerated therapy in
patients with MRSA NP, including those with renal impairment.
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